PATH | VRL
Menu

Hexavalent IPV-Based Combination Vaccines for Public-Sector Markets of Low-Resource Countries

This article, published in Human Vaccines & Immunotherapeutics, evaluates potential hexavalent vaccine candidates containing inactivated polio vaccine (IPV) that could provide reliable, low-cost, and continuous immunization to sustain polio eradication. This product review examines composition, probable time to market, expected cost of goods, presentation, and technical feasibility in order to compare the vaccine candidates.

Author: Mahmood K, Pelkowski S, Atherly D, Sitrin R, Donnelly JJ

Published: 2013

» Visit web page (English)

(Located at www.landesbioscience.com)

Citation: Mahmood K, Pelkowski S, Atherly D, Sitrin R, Donnelly JJ. Hexavalent IPV-Based Combination Vaccines for Public-Sector Markets of Low-Resource Countries. Human Vaccines & Immunotherapeutics. 2013;9(9):1894-1902.

Resource types: Peer-reviewed journal

Diseases/vaccines: Haemophilus influenzae type b (Hib), Hepatitis B, Polio

Topics: Immunization financing, Vaccine safety and performance, Disease/vaccine specific information

Regions: Global